SCHEMBL109071

SCHEMBL109071

COC(=O)c1cc(Br)nc(-c2ccc(C)cc2)c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
RAB9A P51151 4/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
MAPT P10636 7/20 0.41
ALDH1A1 P00352 6/20 0.41
POLB P06746 2/20 0.41
CYP46A1 Q9Y6A2 1/20 0.41
ALPL P05186 1/20 0.41
HSD17B10 Q99714 3/20 0.40
MAPK1 P28482 2/20 0.40
TSHR P16473 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 4/20 0.39
HPGD P15428 4/20 0.39
GAA P10253 2/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL139223 0.89 MAPT (0.47) CA12CA1CA2CA9RAB9A
SCHEMBL23958640 0.88 LMNA (0.49) CA12CA1CA2CA9RAB9A
SCHEMBL110319 0.88 MAPT (0.48) CA12CA1CA2CA9RAB9A
SCHEMBL110248 0.86 KDM4E (0.42) CA12CA1CA2CA9RAB9A
SCHEMBL109836 0.85 ALOX5AP (0.40) RAB9AL3MBTL1MAPTALDH1A1POLB
SCHEMBL110648 0.84 CA12 (0.47) CA12CA1CA2CA9L3MBTL1
SCHEMBL110366 0.83 PDCD1 (0.47) CA12CA1CA2CA9RAB9A
SCHEMBL139273 0.82 MKNK1 (0.45) L3MBTL1ALDH1A1MAPK1KDM4EMEN1
SCHEMBL110399 0.80 KMO (0.45) L3MBTL1MAPTPOLBHSD17B10KDM4E
SCHEMBL110167 0.80 MCL1 (0.46) RAB9AMAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 CA12 3204/4885CA1 2930/4885CA2 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.